JPWO2018125961A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2018125961A5 JPWO2018125961A5 JP2019535356A JP2019535356A JPWO2018125961A5 JP WO2018125961 A5 JPWO2018125961 A5 JP WO2018125961A5 JP 2019535356 A JP2019535356 A JP 2019535356A JP 2019535356 A JP2019535356 A JP 2019535356A JP WO2018125961 A5 JPWO2018125961 A5 JP WO2018125961A5
- Authority
- JP
- Japan
- Prior art keywords
- erythema
- disorders
- dermatitis
- burns
- contact dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010015150 Erythema Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010069808 Electrical burn Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 | |
| US62/440,581 | 2016-12-30 | ||
| PCT/US2017/068636 WO2018125961A1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020512298A JP2020512298A (ja) | 2020-04-23 |
| JPWO2018125961A5 true JPWO2018125961A5 (https=) | 2022-04-19 |
| JP2020512298A5 JP2020512298A5 (https=) | 2022-04-19 |
| JP7141399B2 JP7141399B2 (ja) | 2022-09-22 |
Family
ID=61007849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535356A Active JP7141399B2 (ja) | 2016-12-30 | 2017-12-28 | ポリ－ａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤 |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11034670B2 (https=) |
| EP (1) | EP3562822B1 (https=) |
| JP (1) | JP7141399B2 (https=) |
| KR (1) | KR102606799B1 (https=) |
| CN (1) | CN110167926B (https=) |
| AR (1) | AR110706A1 (https=) |
| AU (1) | AU2017388376B2 (https=) |
| CA (1) | CA3047137A1 (https=) |
| CO (1) | CO2019007906A2 (https=) |
| CY (1) | CY1124565T1 (https=) |
| DK (1) | DK3562822T3 (https=) |
| EA (1) | EA201991412A1 (https=) |
| ES (1) | ES2875841T3 (https=) |
| HR (1) | HRP20210887T1 (https=) |
| HU (1) | HUE054382T2 (https=) |
| IL (1) | IL267676B (https=) |
| JO (1) | JOP20190115B1 (https=) |
| LT (1) | LT3562822T (https=) |
| MA (1) | MA47165B1 (https=) |
| MD (1) | MD3562822T2 (https=) |
| MX (1) | MX393606B (https=) |
| MY (1) | MY199045A (https=) |
| PH (1) | PH12019501529A1 (https=) |
| PL (1) | PL3562822T3 (https=) |
| PT (1) | PT3562822T (https=) |
| RS (1) | RS61895B1 (https=) |
| SA (1) | SA519401894B1 (https=) |
| SI (1) | SI3562822T1 (https=) |
| SM (1) | SMT202100321T1 (https=) |
| TW (1) | TWI773718B (https=) |
| UA (1) | UA124777C2 (https=) |
| WO (1) | WO2018125961A1 (https=) |
| ZA (2) | ZA201904004B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102667386B1 (ko) * | 2015-10-07 | 2024-05-21 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| MX393606B (es) * | 2016-12-30 | 2025-03-19 | Mitobridge Inc | Inhibidores de poli-adp ribosa polimerasa (parp) |
| US12459899B2 (en) | 2019-10-30 | 2025-11-04 | DIGMBIO, Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| CA3213029A1 (en) * | 2021-04-22 | 2022-10-27 | Yuli Xie | Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof |
| CN118076585A (zh) * | 2021-07-23 | 2024-05-24 | 国家医疗保健研究所 | 革兰氏阴性菌外排泵抑制剂 |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| JP2025531246A (ja) | 2022-09-19 | 2025-09-19 | ビーエーエスエフ ソシエタス・ヨーロピア | アゾール系殺有害生物化合物 |
| AU2023377192A1 (en) | 2022-11-07 | 2025-05-22 | Kyoto University | Nitrogen-containing heterocyclic compound |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN120917007A (zh) * | 2023-05-19 | 2025-11-07 | 上海海和药物研究开发股份有限公司 | 一种芳基脲类parp1抑制剂、其制备方法及用途 |
| CN117024357B (zh) * | 2023-07-03 | 2026-02-24 | 山东第二医科大学 | 一种针对brca突变的选择性抑制剂及其用途 |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| CN117510404A (zh) * | 2023-11-29 | 2024-02-06 | 山西永津集团有限公司 | 一种4-氨基烟酸的制备方法 |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN118084678B (zh) * | 2024-03-01 | 2024-09-06 | 长沙唯楚医药科技有限公司 | 一种2-溴-6-氟苯胺的制备方法 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025227032A1 (en) * | 2024-04-26 | 2025-10-30 | Remix Therapeutics Inc. | Methods for degradation of cyclin k and inhibition of cyclin dependent kinases |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082268A1 (en) | 2000-03-20 | 2002-06-27 | Yun Gao | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| US20030087917A1 (en) | 2000-03-27 | 2003-05-08 | Dorothea Strack | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| MXPA06014933A (es) * | 2004-06-30 | 2007-02-28 | Janssen Pharmaceutica Nv | Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1. |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| WO2007011623A1 (en) | 2005-07-15 | 2007-01-25 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
| EP2520567A3 (en) | 2006-02-23 | 2012-12-12 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| EP2010505B1 (en) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| WO2012140642A1 (en) | 2011-04-10 | 2012-10-18 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| AU2014298955B2 (en) | 2013-07-31 | 2018-03-01 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
| CA2948067A1 (en) | 2014-05-07 | 2015-11-12 | Merck Patent Gmbh | Heterocyclyl-butanamide derivatives |
| CN105924434A (zh) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
| MX393606B (es) * | 2016-12-30 | 2025-03-19 | Mitobridge Inc | Inhibidores de poli-adp ribosa polimerasa (parp) |
-
2017
- 2017-12-28 MX MX2019007870A patent/MX393606B/es unknown
- 2017-12-28 HR HRP20210887TT patent/HRP20210887T1/hr unknown
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/hu unknown
- 2017-12-28 MA MA47165A patent/MA47165B1/fr unknown
- 2017-12-28 SI SI201730772T patent/SI3562822T1/sl unknown
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/ja active Active
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/ko active Active
- 2017-12-28 MY MYPI2019003419A patent/MY199045A/en unknown
- 2017-12-28 EA EA201991412A patent/EA201991412A1/ru unknown
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 SM SM20210321T patent/SMT202100321T1/it unknown
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/da active
- 2017-12-28 PT PT178326948T patent/PT3562822T/pt unknown
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/lt unknown
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/ro unknown
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 PL PL17832694T patent/PL3562822T3/pl unknown
- 2017-12-28 ES ES17832694T patent/ES2875841T3/es active Active
- 2017-12-28 RS RS20210653A patent/RS61895B1/sr unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en not_active Ceased
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 UA UAA201908940A patent/UA124777C2/uk unknown
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/ar active
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/zh active Active
- 2017-12-29 AR ARP170103718A patent/AR110706A1/es active IP Right Grant
- 2017-12-29 TW TW106146555A patent/TWI773718B/zh active
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/ar unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/es unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/el unknown
- 2021-06-09 US US17/342,873 patent/US11993585B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2018125961A5 (https=) | ||
| CL2021003098A1 (es) | Compuestos inmunomoduladores diméricos contra mecanismos basados en cereblon (divisional de la solicitud no. 202100061) | |
| MX2019003821A (es) | Composiciones de aminoacidos y usos de las mismas. | |
| ATE341330T1 (de) | Alpha-hydroxy-2-methylen-10-nor-pregnacalcifero und seine anwendungen | |
| JO2448B1 (en) | Topical pharmaceutical compositions for the treatment of dermatitis | |
| WO2006040688B1 (en) | Inhibitors of acetylcholinesterase for treating skin diseases | |
| NO20083637L (no) | anvendelse av alkandikarboksylsyrer og retinoider for behandling av rosacea og andre inflammatoriske hudsykdommer | |
| UY27924A1 (es) | Compuestos tipo diarilureas fluoradas | |
| DE60231050D1 (de) | Verwendung von Totarol zur Behandlung von Pruritus | |
| RU2015112839A (ru) | Составы, содержащие идебенон, n-ацетил-s-фарнезил-l-цистеин и эрготионеин, и их применение | |
| RU2013150536A (ru) | Способ и топическая композиция для обработки ран, содержащая seaprose и его применение | |
| CU20160089A7 (es) | PIPERIDINILTETRAHIDROQUINOLINAS SUSTITUIDAS COMO RECEPTORES ADRENÉRGICOS a2C | |
| CU24390B1 (es) | Piperidinil-tetrahidroquinolinas sustituidas | |
| MX2016008795A (es) | Composiciones y métodos de tratamiento de afecciones inflamatorias de la piel, utilizando alantoína. | |
| ATE402924T1 (de) | Pyridiniumsalze und deren verwendung | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| EA200601607A1 (ru) | Сульфонамидные соединения для лечения нейродегенеративных расстройств | |
| JP2015526499A5 (https=) | ||
| ATE502636T1 (de) | Topische zusammensetzungen mit telmestein zur behandlung von dermatologischen erkrankungen | |
| SE0401943D0 (sv) | New use | |
| EP4388098A4 (en) | COMPOSITION COMPRISING AN RNA THERAPEUTIC AGENT TARGETING FAT10 AND USES OF THIS AGENT TO TREAT DISORDERS CHARACTERIZED BY ABNORMAL LIPID ACCUMULATION | |
| FR3115680B1 (fr) | Compositions pour le traitement du psoriasis. | |
| ATE516028T1 (de) | Zusammensetzung zur behandlung von hauterkrankungen | |
| WO2006110577A3 (en) | Use of fril proteins for reducing the production of pro-inflammatory cytokines | |
| CN103494725A (zh) | 一种用于消炎护肤的芦荟啫喱 |